Shots:

• SpringWorks and Dana-Farber collaborated to evaluate nirogacestat with anti-B-cell maturation antigen (BCMA) agents in multiple preclinical multiple myeloma models
• SpringWorks will fund the work and will retain an option to exclusively license any new IP emerging from the research collaboration
• The collaboration will utilize preclinical in vivo models from the Mitsiades Lab to simulate the MM tumor microenvironment. The research will deploy functional genomics approaches to explore determinants of response and mechanisms of resistance to GSI + BCMA combination therapy

  | Ref: Globe Newswire | Image: Neurofibromatosis Network